Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 10% vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Reduction of intracranial pressure and cerebral edema,Promotion of diuresis in patients with acute renal failure (oliguric phase) or to prevent renal failure in certain conditions,Reduction of intraocular pressure in acute glaucoma,Enhancement of urinary excretion of toxic substances (e.g., in overdoses),Adjunct in dialysis or hemofiltration (off-label)
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Terminal half-life: 1.1–1.6 hours; prolonged to 6–36 hours in renal impairment
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Mannitol is not metabolized in the body. It is eliminated unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Renal: 90% as unchanged drug; <10% metabolized in liver to fructose and glucose; fecal: negligible
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Negligible (<2%); does not bind to plasma proteins
98% bound to sex hormone-binding globulin (SHBG) and albumin.
0.36–0.5 L/kg; distributes primarily in extracellular fluid, limited CNS penetration due to hydrophilic nature
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
IV: 100%; oral: negligible (<10%) due to poor absorption and osmotic diarrhea
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolality.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
No specific Child-Pugh based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
0.25-1 g/kg intravenously as a 10% solution over 30-60 minutes, repeated every 6-8 hours as needed.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Start at lower end of dosing range (0.25-0.5 g/kg) due to decreased renal function; monitor fluid and electrolyte balance closely.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
None
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Use with caution in patients with congestive heart failure due to risk of pulmonary edema from fluid overload,Monitor serum electrolytes (especially sodium and potassium) and renal function during therapy,May cause acute kidney injury with excessive doses or pre-existing renal impairment,In patients with intracranial hemorrhage, avoid rapid reduction of intracranial pressure,May cause expansion of extracellular fluid volume leading to pulmonary edema in patients with compromised cardiac function
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Anuria due to severe renal disease,Severe pulmonary edema or congestion,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Avoid high-sodium foods and salt substitutes to prevent electrolyte imbalance; maintain adequate fluid intake unless fluid restriction is advised; no specific food interactions, but monitor for changes in blood glucose if diabetic.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with clinical use is low. Second trimester: Generally safe for short-term use when indicated (e.g., elevated intracranial pressure), but avoid prolonged exposure to prevent fetal dehydration or electrolyte imbalances. Third trimester: Use cautiously; osmotic diuresis may cause maternal hypovolemia, potentially reducing placental perfusion and leading to fetal distress.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Mannitol is excreted into breast milk in low concentrations (estimated M/P ratio <0.1) due to its high molecular weight and hydrophilicity. Oral bioavailability in infants is negligible, and no adverse effects have been reported. However, caution is advised if used repeatedly or in high doses, as theoretical risk of neonatal electrolyte imbalance exists.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
Pregnancy does not significantly alter the pharmacokinetics of mannitol. Standard adult dosing (0.25–2 g/kg as a 10% solution) is recommended, with adjustments based on renal function, volume status, and therapeutic response. Avoid excessive doses to prevent maternal volume overload and electrolyte disturbances.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
Administer via in-line filter to prevent crystallization; monitor serum sodium and osmolality closely to avoid hypernatremia and osmotic demyelination; ensure adequate urine output before use to avoid pulmonary edema; use with caution in patients with congestive heart failure or renal impairment; can cause transient volume expansion followed by diuresis.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
This medication may cause increased thirst and frequent urination.,Report any chest pain, difficulty breathing, or swelling of ankles/legs.,Avoid consuming salty foods to prevent fluid retention.,Do not stop taking without consulting your doctor.,Inform your doctor if you have kidney disease, heart failure, or are on a low-salt diet.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 10% vs ANDROID 5, answered by our medical review team.
MANNITOL 10% is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 10% and ANDROID 5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 10% is: 0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 10% and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 10% is classified as Category A/B. Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with c. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.